IMMIX BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.98 USD | -7.04% |
|
-2.94% | -71.39% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 47.02 | 31.89 | 137.5 | 52.3 | - |
| Enterprise Value (EV) 1 | 47.02 | 18.46 | 120 | 40.31 | 66.76 |
| P/E ratio | -0.54 x | -3.88 x | -7.78 x | -2.13 x | -1.96 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | -2.25 x | -7.44 x | -1.84 x | -2.57 x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Price to Book | - | - | - | - | - |
| Nbr of stocks (in thousands) | 13,209 | 13,927 | 19,867 | 26,414 | - |
| Reference price 2 | 3.560 | 2.290 | 6.920 | 1.980 | 1.980 |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | -8.217 | -16.14 | -21.96 | -26.01 |
| EBIT 1 | - | -8.219 | -16.14 | -21.96 | -26.16 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -8.219 | -15.57 | -21.44 | -26.55 |
| Net income 1 | -24.38 | -8.23 | -15.43 | -21.47 | -26.59 |
| Net margin | - | - | - | - | - |
| EPS 2 | -6.640 | -0.5900 | -0.8900 | -0.9300 | -1.010 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT 1 | - | -3.795 | -2.521 | -3.721 | -4.524 | -5.376 | -5.59 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -3.795 | -2.493 | -3.592 | -4.337 | -5.147 | -5.322 |
| Net income 1 | -1.535 | -3.8 | -2.48 | -3.576 | -4.281 | -5.09 | -5.259 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -0.1100 | -0.2700 | -0.1800 | -0.2400 | -0.2300 | -0.2400 | -0.2200 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/9/22 | 3/27/23 | 5/12/23 | 8/11/23 | 11/13/23 | 3/29/24 | 5/9/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 14.5 |
| Net Cash position 1 | - | 13.4 | 17.5 | 12 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.5558 x |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | - | 0.05 | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/28/22 | 3/27/23 | 3/29/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -71.39% | 52.3M | |
| +2.99% | 95.18B | |
| -4.34% | 37.55B | |
| -10.41% | 33.75B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B |
- Stock Market
- Equities
- IMMX Stock
- Financials Immix Biopharma, Inc.
